Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
aTyr Pharma, Inc. (NASDAQ: LIFE) is at the forefront of the discovery and clinical development of pioneering medicines targeting severe, rare diseases. Leveraging unique insights into physiocrine biology, a newly identified group of physiological modulators, aTyr aims to deliver breakthrough treatments to patients in need.
The company's flagship candidate, resolaris™, is a first-in-class intravenous protein therapeutic designed to address rare myopathies with an immune component. Resolaris™ is undergoing a series of Phase 1b/2 clinical trials, including trials for adult patients with facioscapulohumeral muscular dystrophy (FSHD), limb girdle muscular dystrophy (LGMD) 2B or FSHD, and patients with an early onset form of FSHD.
aTyr Pharma holds a substantial intellectual property portfolio, featuring 70 issued or allowed patents and over 240 pending patent applications, all of which are solely owned or exclusively licensed by the company. This robust IP estate underpins their strategic focus on severe, rare diseases characterized by immune dysregulation.
One of the company’s notable recent achievements includes the development of efzofitimod, a first-in-class NRP2-targeting immunomodulator. Preclinical models have demonstrated that efzofitimod has significant immune regulatory functions, improving disease outcomes and mitigating fibrosis, particularly in rheumatoid arthritis and associated lung fibrosis.
In addition to its innovative drug pipeline, aTyr Pharma has bolstered its leadership and expertise by enlisting Dr. Frederick to guide corporate affairs and commercial strategies for efzofitimod in interstitial lung disease (ILD).
For the most current updates and detailed information, investors can contact Ashlee Dunston, Director of Investor Relations and Public Affairs, at adunston@atyrpharma.com.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced it will present a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 10-14, 2021. The poster, titled ATYR2810, an anti-NRP2 monoclonal antibody, targets tumor associated macrophages, will showcase the therapeutic potential of ATYR2810, designed to block the interaction between NRP2 and VEGF in specific aggressive tumors. This investigational drug is currently in IND-enabling studies and represents a significant milestone in aTyr’s innovative research on monoclonal antibodies.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the closing of a public offering of 10,781,250 shares at $8.00 each, raising gross proceeds of $86.3 million. This includes the full exercise of the underwriters’ option to purchase additional shares. The offering was managed by Piper Sandler and RBC Capital Markets, among others. The funds raised will support aTyr's ongoing research and development efforts, particularly in innovative medicines involving tRNA synthetases. The press release clarifies that this announcement does not constitute an offer to sell securities.
aTyr Pharma, a biotherapeutics company focused on innovative medicines, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, scheduled for September 20-23, 2021. The presentation, led by President and CEO Sanjay S. Shukla, is set for September 22, 2021, at 3:45 p.m. ET. Attendees will also have the opportunity to engage in virtual one-on-one meetings with management. A replay will be accessible on the company's website post-event.
aTyr Pharma, a clinical-stage biotherapeutics company, announced the pricing of its underwritten public offering of 9,375,000 shares at $8.00 per share, aiming for gross proceeds of approximately $75 million. The offering includes a 30-day option for underwriters to purchase an additional 1,406,250 shares. The deal is expected to close by September 20, 2021, subject to customary conditions. Piper Sandler and RBC Capital Markets are the joint book-running managers, while Laidlaw & Company and Roth Capital Partners serve in advisory roles.
aTyr Pharma, Inc. (Nasdaq: LIFE) has announced an underwritten public offering of its common stock, with underwriters being granted a 30-day option to purchase additional shares. This offering is subject to market conditions and there is no assurance of completion or specific terms. The offering is made under a shelf registration statement declared effective on August 23, 2021. Piper Sandler and RBC Capital Markets are the joint book-running managers for the offering. A final prospectus supplement will provide more details.
aTyr Pharma announced promising results from its Phase 1b/2a trial of ATYR1923 in patients with pulmonary sarcoidosis. The trial demonstrated that ATYR1923 was safe, well-tolerated, and resulted in a 58% reduction in steroid usage in the 5.0 mg/kg group, with one-third of patients able to taper off steroids completely. Improvements in lung function were noted, with a 3.3% increase in forced vital capacity. Overall, the study showed significant efficacy across key endpoints, paving the way for further development and potential FDA consultation to initiate a registrational trial next year.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced significant progress in its clinical trials for ATYR1923 aimed at treating pulmonary sarcoidosis, with results from a Phase 1b/2a trial expected by mid-September 2021.
The company confirmed the completion of patient visits and showcased a positive safety profile for ATYR1923 in preliminary studies. Additionally, they reported second-quarter 2021 financials, with cash reserves of $44.1 million and R&D expenses at $7.7 million, reflecting ongoing investment in innovative therapies.
aTyr Pharma, Inc. (Nasdaq: LIFE) has expanded its research collaboration with The Ohio State University to explore immune mechanisms and identify biomarkers of efficacy for its lead therapy, ATYR1923, targeting pulmonary sarcoidosis. Led by Dr. Elliott Crouser, the collaboration aims to analyze blood samples from sarcoidosis patients to understand granuloma formation and potentially improve treatment outcomes. Given that existing treatments offer limited efficacy, this study may significantly impact patient management. The findings from a related pilot study will be presented at the upcoming European Respiratory Society Congress.
On August 9, 2021, aTyr Pharma (Nasdaq: LIFE) announced the acceptance of two abstracts for its lead candidate, ATYR1923, at the 2021 European Respiratory Society Congress, scheduled online from September 5-8. The first abstract discusses ATYR1923's role in reducing biomarkers in COVID-19 pneumonia, while the second focuses on its inhibition of sarcoid granuloma formation. aTyr is developing ATYR1923 for severe inflammatory lung diseases and has completed enrollment in a Phase 1b/2a trial for pulmonary sarcoidosis, with a recent Phase 2 trial showing promising results in COVID-19 patients.
aTyr Pharma (Nasdaq: LIFE) announced on August 3, 2021, that it will report its second quarter 2021 financial results and provide a corporate update on August 10, 2021, after the market closes. A conference call and webcast are scheduled for the same day at 5:00 PM EDT. The company focuses on developing innovative medicines based on novel biological pathways, particularly their clinical-stage product candidate, ATYR1923, aimed at treating inflammatory lung diseases.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
What does aTyr Pharma, Inc. specialize in?
What is aTyr Pharma's leading drug candidate?
In which clinical trial phases is resolaris™ currently?
What is the significance of physiocrine biology for aTyr Pharma?
How strong is aTyr Pharma's intellectual property portfolio?
What is efzofitimod?
Who can investors contact for more information?
What recent strategic addition did aTyr Pharma make?
When will aTyr Pharma's ticker symbol change take effect?
What is the focus of aTyr Pharma's key programs?
